Register Now: Webinar on Immunotherapy for Brain Tumors


Join Us for a Webinar on Immunotherapy for Brain Tumors

Immunotherapy – particularly the use of checkpoint inhibitors – has been a revolution in cancer care. However, not all cancers respond to checkpoint inhibitors, and the response rates are only 20-30%. Given the negative results in studies to treat one of the most deadly brain tumors, glioblastomas (GBM), using checkpoint inhibitors, novel immunotherapy strategies are needed.  

Current approaches have employed the concept of multimodal strategies with immunotherapy. The central concept is to cause focal disruption to “kindle” a systemic immune response. For brain tumors, modalities such as focused ultrasound, stereotactic radiosurgery, neoadjuvant surgery, and laser ablation are being combined with immunotherapy strategies in hopes of generating an antitumor immune response. 

Please register to join us at 1:00 PM Eastern on Monday, February 24, when Michael Lim, MD, will discuss the mechanisms of “kindling” and review the state of multimodal immunotherapy in GBM.

Michael Lim, MD
Johns Hopkins University School of Medicine

Immunotherapy for Brain Tumors

Monday, February 24, 2020
1:00 PM Eastern US

About the Speaker

Dr. Michael Lim is a Professor of Neurosurgery, Oncology, Otolaryngology, and Radiation Oncology at the Johns Hopkins University School of Medicine.

He is also the Director of the Brain Tumor Immunotherapy Program at Johns Hopkins. His primary research interest is developing immune-based therapies against brain tumors. His research laboratory is focused on understanding the mechanisms of immune evasion by primary brain tumors, and their findings are directed towards translation to novel therapies against brain tumors.

In addition to running a laboratory, Dr. Lim also directs the immunotherapy clinical trials program at Johns Hopkins. He currently serves as the principal investigator of several large brain tumor immunotherapy clinical trials based on findings from his laboratory. 

Dr. Lim’s surgical interest is in both benign and malignant brain tumors, with a particular interest in gliomas (including ependymoma), meningioma, pituitary tumors, and skull base tumors. He has extensive experience in new and innovative neurosurgical techniques including image guided surgery, microsurgery, minimally invasive procedures, and endoscopic surgery. 

He obtained his MD from the Johns Hopkins University School of Medicine and  completed his residency in Neurosurgery at Stanford University Hospital.